FDA Oversight Of Clinical Trials Needs More Muscle, OIG Report Says
This article was originally published in The Gray Sheet
Executive Summary
FDA lacks the data it needs to protect patients enrolled in clinical trials, says a Sept. 28 1report from the HHS Office of Inspector General
You may also be interested in...
“For Cause” Inspections Find Galloping Clinical Trial Violation Rate
The violation rate for clinical trial sponsors shot up in fiscal year 2007, hitting a 10-year high, with FDA finding many of the problems during inspections triggered by complaints, according to CDRH
“For Cause” Inspections Find Galloping Clinical Trial Violation Rate
The violation rate for clinical trial sponsors shot up in fiscal year 2007, hitting a 10-year high, with FDA finding many of the problems during inspections triggered by complaints, according to CDRH
FDA Bill Signed Into Law; CDRH Set To Implement Fee-Based e-Registration
President Bush Sept. 27 signed into law the FDA Amendments Act, setting in motion significant reforms in the way the agency will oversee the safety of health care products